CAPLIPOINT

Caplin Point Laboratories Limited, through its subsidiaries Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL), has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic product manufacturer. The acquired portfolio, which includes select oncology injectables, has an addressable market of $473.2 million as of August 2025 and will be commercialized in the U.S. and extended to non-U.S. markets such as Mexico, Canada, the EU, and Brazil. Caplin Point, a fast-growing pharmaceutical company catering to emerging markets, has been recognized for its consistent growth and achievements, including appearing on Forbes’ “Asia’s 200 Best Under a Billion” list seven times in the last decade. The company’s subsidiaries, CSL and COL, are actively involved in developing, filing, and commercializing sterile and oncology products for regulated and non-regulated markets globally.